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Summary
Ligand-induced activation of the epidermal growth
factor receptor (EGFR) initiates multiple signal-trans-
duction pathways as well as trafficking events that
relocalize the receptors from the cell surface to intra-
cellular endocytic compartments. Although there is
growing awareness that endocytic transport can play
a direct role in signal specification, relatively little is
known about the molecular mechanisms underlying
this link. Here we show that human Sprouty 2 (hSpry2),
a protein that has been implicated in the negative
regulation of receptor tyrosine kinase (RTK) signaling
[1], interferes with the trafficking of activated EGFR
specifically at the step of progression from early to
late endosomes. This effect is mediated by the binding
of hSpry2 to the endocytic regulatory protein, hepato-
cyte growth factor-regulated tyrosine kinase substrate
(Hrs), and leads to a block in intracellular signal prop-
agation. These observations suggest that EGFR sig-
naling is controlled by a novel mechanism involving
trafficking-dependent alterations in receptor compart-
mentalization.
Results and Discussion
The signal output of RTKs is under the tight control of
positive and negative regulators. Sprouty (Spry) pro-
teins comprise a family of structurally related negative-
feedback regulators of RTK signaling. Because of their
ability to interact with various signaling molecules,
Spry proteins are thought to exert their inhibitory effects
by interfering with the formation of signaling complexes
that are required for RTK-mediated signal flow [2]. How-
ever, the spatio-temporal regulation of these interac-
tions remains largely unknown. Several studies have re-
ported the presence of Spry proteins in cytoplasmic
vesicular structures [3–6]. Moreover, in some cases
these structures have been shown to contain internal-
ized EGFRs, indicating their endosomal nature [3, 5].
Given the well-established link between the endocytic
fate of RTKs and their signaling capacity, we sought to
determine the functional significance of endosome-
localized Spry.
*Correspondence: dafna.bar-sagi@med.nyu.eduBecause most Spry localization studies carried out to
date have been performed with ectopically expressed
Spry, we set out to examine the localization of endoge-
nous Spry2 by indirect immunofluorescence staining
by using Spry2 antibody. To this end, we have exploited
two cell lines, C2C12 murine myoblasts and MIAPaCa-2
human pancreatic tumor cells, in which the expression
levels of Spry were found to be relatively high ([7], our
unpublished observation). As illustrated in Figure 1A
and Figure S1A, the staining pattern of endogenous
Spry2 consisted predominantly of cytoplasmic Spry2-
enriched punctae. We ascertained the specificity of
staining from the fact that the preabsorption of the
antibodies with purified Spry2 proteins abrogated the
immunofluorescence signal (Figure S1A).
In order to determine the identity of the Spry2-
containing structures, we examined the colocalization
of Spry2 with the early-endosomal marker Rab5 or the
late-endosomal marker Rab7. Under serum-deprived
conditions, there was no detectable colocalization be-
tween Spry2 and Rab5 (Figure 1A). However, after EGF
stimulation, most of the Spry2-containing structures
were found juxtaposed to Rab5-positive endosomes
(Figure 1A). The spatial overlap between Spry2 and early
endosomes was detected as early as 10 min after EGF
addition and persisted for up to 2 hr. The same localiza-
tion pattern was displayed by ectopically expressed
hSpry2 (Figure S1B). Moreover, no colocalization of
hSpry2 and Rab7 was observed at any point after EGF
addition (Figure S1C). Together, these observations
indicate that ligand-dependent activation of EGFR
induces the stable association of Spry2 with early endo-
somes. Based on colocalization studies with caveolin, it
appears that most of the Spry2-containing structures
observed in the absence of growth-factor stimulation
correspond to the caveosome (Figure S1D).
Endocytosis is widely viewed as a means to terminat-
ing signaling via degradation of activated receptor com-
plexes after their internalization from the cell surface.
However, recent studies have uncovered a role for
endocytic organelles as signaling platforms [8]. Given
the EGF-dependent association of hSpry2 with the early
endosome, we have reasoned that it might function by
affecting the endocytic trafficking of EGFR. To test this
idea, we monitored the endocytic movement of EGFR
in the presence or absence of hSpry2. Within 10 min of
EGF stimulation, most of the ligand-bound receptors
were found in early endosomes, as evidenced by their
colocalization with the early endosomal marker EEA1
(Figures 1B and 1C). By 30 min, approximately 60%–
70% of the receptor molecules colocalized with Rab7,
indicating their progression to late-endosomal compart-
ments (Figures 1D and 1E). In contrast, in cells express-
ing hSpry2, only 30% of the receptors translocated to
late-endosomal compartments, whereas 70% remained
associated with early endosomes up to 2 hr after stimu-
lation (Figures 1C and 1E). The same effect was observed
with an hSpry2 mutant that cannot interact with c-Cbl
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456Figure 1. Spry2 Localizes to the Early Endosome and Impedes EGFR Trafficking from Early to Late Endosomes
(A) Endogenous Spry2 colocalizes with the early endosomal marker Rab5 after EGF stimulation. C2C12 cells were stimulated with 100 ng/ml EGF
for 15 min and immunostained with Spry2 and Rab5 antibodies. Red, Spry2; green, Rab5; and blue, 406-diamidino-2-phenylindole (DAPI) nuclear
counterstaining. Images on the right side represent a higher magnification of the boxed areas.
(B) COS-1 cells were serum starved and transfected with the HA-hSpry2 construct. Cells were stimulated with 100 ng/ml Texas red EGF (TR-EGF)
for the indicated time periods and immunostained with EEA1 (green) and Spry2 (blue) antibodies. Insets represent a higher magnification of the
boxed areas.
(C) Quantification of EGFR trafficking to early endosomes. Data are presented as percentages of EEA1-labeled Texas red EGF-containing ves-
icles out of total number of Texas red EGF-containing vesicles per cell. Values reflect the mean6 standard deviation (SD) of three independent
experiments, with an average of 30 cells scored per experiment.
(D) COS-1 cells were serum starved and transfected with GFP-Rab7 and HA-hSpry2 constructs. Cells were stimulated as in Figure 1B and im-
munostained with Spry2 antibody (blue). Insets represent higher magnifications.
(E) Quantification of EGFR trafficking to late endosomes. Data are presented as percentages of Rab7-labeled Texas red EGF-containing vesicles
out of the total number of Texas red EGF-containing vesicles per cell. Values reflect the mean 6 standard deviation (SD) of three independent
experiments, with an average of ten cells scored per experiment. Scale bars represent 10 mm in all panels.
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457(DCbl) (Figures 1C and 1E). These observations indicate
that hSpry2 expression interferes with the trafficking of
EGFR from early to late endosomes through a c-Cbl in-
dependent mechanism. As might be predicted, this traf-
ficking defect is associated with the attenuation of li-
gand-induced EGFR degradation (Figures S2A and S2B).
To rule out the possibility that the effects of hSpry2 on
EGFR trafficking are due to overexpression, we have ex-
amined the endocytic fate of EGFR in cells depleted of
hSpry2 by RNA interference (RNAi). For this analysis,
we elected to use the pancreatic cancer cell line
MIAPaCa-2 because the endogenous levels of Spry2
are constitutively high in these cells. As illustrated in
Figure 2A, the expression of hSpry2 shRNA was accom-
panied by a substantial reduction (approximately 90%)
in the level of hSpry2 protein. In cells expressing control
shRNA, stimulation with Texas red EGF rapidly induced
receptor internalization and trafficking to early endo-
somes, as evidenced by their colocalization with EEA1
(Figure 2B, 10 min). However, endocytic progression be-
yond this step was halted; the ligand-bound EGFR re-
mained associated with EEA1-positive structures for
up to 2 hr (Figures 2B and 2C). In contrast, in hSpry2-
depleted cells, EGFRs gradually dissociated from early
endosomes, as illustrated by decreased colocalization
with EEA1 over time (Figures 2B and 2C) and the accu-
mulation of the receptor in the LAMP1-positive late-
endosomal compartment (Figure S3). The effect of
hSpry2 shRNA was reversed in the presence of the
shRNA-insensitive hSpry2 mutant, indicating that the
consequences of hSpry2 shRNA expression reflect
the specific targeting of hSpry2 (Figures 2D and 2E).
These observations are in agreement with the hSpry2
ectopic expression data (Figure 1) and provide further
support for the idea that hSpry2 interferes with the
progression of internalized receptors from early to late
endosomes.
We have observed that the majority of EGFR-contain-
ing endosomes in hSpry2-expressing cells are also pos-
itive for hSpry2 (Figure S4). This observation suggests
that hSpry2 might exert its effect on EGFR trafficking
by targeting the endocytic sorting machinery itself.
The sorting of activated EGFR from early to late endo-
somes has been shown to depend on the multidomain
protein Hrs [9]. Consequently, Hrs loss of function or
overexpression results in the accumulation of EGFR in
enlarged early endosomes [10, 11]. Given the resem-
blance of this effect to that induced by the expression
of hSpry2, we have examined the possibility that hSpry2
inhibits EGFR trafficking by modulating Hrs function
at early endosomes. As illustrated in Figures 3A–3C,
hSpry2 interacts with Hrs in a time-dependent manner
after the addition of EGF, and this interaction takes
place at the early endosome (Figure S5A).
The role of Hrs in promoting endocytic sorting is ac-
complished through multiple protein-protein interac-
tions. Of particular relevance to this study is the recent
demonstration that Hrs binds directly to the tumor-
susceptibility gene 101 (Tsg101) and that this binding
is required for EGFR transport from early to late endo-
somes [12–14]. As illustrated in Figure 3D, the expres-
sion of hSpry2 resulted in a dose-dependent attenuation
of Hrs/Tsg101 interactions. Conversely, increasing the
amount of Tsg101 disrupted the hSpry2 and Hrsinteraction, indicating that hSpry2 competes with
Tsg101 for binding to Hrs (Figure S5B). The expression
of hSpry2 had no effect on Hrs tyrosine phosphorylation
(Figure S5C) or endosomal localization (Figure S5D).
Taken together, these results support the idea that
hSpry2 may impede EGFR exit from early endosomes
by interfering with the interaction of Hrs with Tsg101.
In order to confirm that the interaction of hSpry2 with
Hrs is required for its interference with EGFR trafficking,
we have utilized a serine-phosphorylation-deficient
hSpry2 mutant, hSpry2 S112A/S121A [15], which in
comparison to wild-type hSpry2 displays a markedly re-
duced ability to interact with Hrs (Figure 3E) and com-
pete off Tsg101 (Figure 3F). Significantly, the movement
of EGFR from early to late endosomes was not altered in
the presence of hSpry2 S112A/S121A (Figures 3G and
3H). Likewise, the hSpry2-induced attenuation of ligand-
dependent EGFR degradation did not take place upon
the expression of hSpry2 S112A/S121A (Figures S2A
and S2B). Together, these results indicate that the inhib-
itory effect of hSpry2 on the trafficking of EGFR from
early to late endosomes is dependent on hSpry2/Hrs
interaction. The molecular details of these interactions
and the extent to which they represent a direct associa-
tion between the two proteins remain to be established.
It is becoming increasingly recognized that the or-
dered propagation of mitogen-activated protein kinase
(MAPK) activation from the plasma membrane to early-
and late-endosomal compartments directly contributes
to both signal output and biological outcome [8, 16, 17].
Because hSpry2 hinders the movement of activated re-
ceptors through the endocytic pathway, this effect
could influence the spatial segregation of signaling
events along the endocytic pathway. To examine this
possibility, we assessed the spatiotemporal activation
of the RTK-Ras-ERK cascade by fluorescence micros-
copy. Early and late endosomes can be often distin-
guished on the basis of their morphological appearance;
whereas early endosomes are located primarily in the
cell periphery, late endosomes are oriented closer to
the nucleus and often form enlarged structures [18,
19]. To ascertain the applicability of this morphological
distinction to the experimental system used in the pres-
ent study, we stained the endocytic structures with the
relevant markers and assessed their proximity to the nu-
cleus by nuclear counterstaining with 406-diamidino-2-
phenylindole (DAPI) (data not shown). Employing these
criteria, we used Texas red EGF and an antibody that
recognizes only the phosphorylated form of ERK to de-
termine the subcellular localization of endocytosed
receptors and activated ERK in each of these compart-
ments. In unstimulated cells, most ligand-bound EGFRs
were detected at the plasma membrane, and there was
no significant pERK staining (Figure 4A, upper panel).
However, after 10 min of EGF stimulation, an increase
of pERK staining was observed in peripheral early endo-
somes, where pERK colocalized with Texas red EGF
(Figure 4A, middle panel). After 30 min of stimulation,
Texas red EGF and pERK signals relocalized to the
enlarged perinuclear compartments corresponding to
late endosomes (Figure 4A, lower panel). A similar
movement of pERK signal along the endocytic pathway
upon EGF stimulation has also been demonstrated in an
earlier study [20]. This relocalization event was blocked
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458Figure 2. Depletion of Spry2 Enhances EGFR Trafficking
(A) MIAPaCa-2 cells were transfected with scramble (control) and hSpry2 shRNAs. Whole-cell lysates were immunoblotted (IB) with the indicated
antibodies.
(B) Control and hSpry2-depleted cells were serum starved for 16 hr. Cells were stimulated with 100 ng/ml Texas red EGF (TR-EGF) for 10 and
30 min and stained with EEA1 antibody (green) and DAPI. The boxed area is magnified on the right side. Scale bars represent 10 mm in all panels.
(C) Quantification of EGFR trafficking to early endosomes in MIAPaCa-2 cells. Data are presented as described in Figure 1C. Values reflect the
mean 6 SD of three independent experiments, with an average of 30 cells scored per experiment.
(D) MIAPaCa-2 cells were transfected with scramble and hSpry2 shRNA with/without shRNA-resistant hSpry2 mutant (hSpry2 mut). Whole-cell
lysates were immunoblotted with the indicated antibody.
(E) Quantification of EGFR trafficking to early endosomes in MIAPaCa-2 cells. Cells were transfected with control and hSpry2 shRNA with/
without hSpry2 mut and serum starved for 16 hr. Cells were stimulated with 100 ng/ml Texas red EGF (TR-EGF) for 60 min and stained with
EEA1 antibody. Data are presented as described in (C). Error bars represent the standard error of the mean (SEM); differences between exper-
iments were examined with the Student’s t test (*p < 0.05).
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459Figure 3. hSpry2 Disrupts Hrs and Tsg101 Interaction
(A) Interaction of ectopically expressed hSpry2 and Hrs. CHOK1 cells were transfected with HA-hSpry2 and Flag-Hrs expression plasmids. Im-
munoprecipitation (IP) and immunoblotting (IB) were carried out with the indicated antibodies. WCL; whole-cell lysates.
(B) Interaction of endogenous Spry2 with endogenous Hrs. MIAPaCa-2 cells were immunoprecipitated with Spry2 antibody or nonimmunized
rabbit serum and immunoblotted with the indicated antibodies.
(C) The interaction of hSpry2 with Hrs is augmented in the presence of EGF. CHOK1 cells were transfected with HA-hSpry2 and Flag-Hrs expres-
sion plasmids. Serum-starved cells were stimulated with 100 ng/ml EGF for the indicated time periods. IP and IB were carried out with indicated
antibodies.
(D) The binding of hSpry2 to Hrs displaces Tsg101. CHOK1 cells were transfected with HA-hSpry2, Flag-Hrs, and Myc-Tsg101 expression plas-
mids as indicated. IP and IB were carried out with the indicated antibodies.
(E) hSpry2 S112A/S121A mutant does not interact with Hrs. CHOK1 cells were transfected with Flag-Hrs together with either HA-hSpry2 or
HA-hSpry2 S112A/S121A expression plasmid. IP and IB were carried out with the indicated antibodies.
(F) CHOK1 cells were transfected with Flag-Hrs, Myc-Tsg101, and hSpry2 constructs as indicated. IP and IB were carried out with the indicated
antibodies.
(G) COS-1 cells were serum starved and transfected with GFP-Rab7 and the indicated hSpry2 constructs. Cells were stimulated with 100 ng/ml
Texas red EGF (TR-EGF) for 60 min and immunostained with Spry2 antibody (blue). Scale bars represent 10 mm.
(H) Quantification of EGFR trafficking to late endosomes. Data are presented as described in Figure 1E. Error bars represent SEM; differences
between experiments were examined with the Student’s t test (*p < 0.05).
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460Figure 4. hSpry2 Impairs the Propagation
of ERK Signaling through the Endocytic
Pathway
(A and B) COS-1 cells were serum starved
and stimulated with 100 ng/ml Texas red
EGF for the indicated intervals in the absence
(A) or presence (B) of HA-hSpry2 expression.
Cells were stained with phospho ERK anti-
body (green). Images on the right side repre-
sent a higher magnification of the boxed area.
Scale bars represent 10 mm in all panels.
(C) Quantification of late-endosome-asso-
ciated pERK. Values are presented as per-
centages of cells displaying late-endosomal
pERK signal at 30 min after EGF stimulation
and reflect the mean 6 SD of three indepen-
dent experiments, with an average of 30 cells
scored per experiment.in cells expressing hSpry2 (Figures 4B and 4C). Instead,
in these cells, pERK and activated EGFR remained
associated with the peripheral early endosomal com-
partments (Figure 4B, lower panel). These observations
indicate that hSpry2 interferes with the orderedprogression of ERK signal from early to late endosomes.
A similar regulatory principle governs the activity of an-
other negative regulator of RTK signaling, Sef (protein
product of sef, similar expression to fgf genes), which re-
sides in the Golgi apparatus and inhibits MEK/ERK
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461signaling specifically in this location [21]. Thus,the spa-
tial restriction of ERK activity may constitute a common
mode by which regulators of RTK signaling operate.
Multiple lines of evidence indicate that the sorting of
receptors to different membrane-bound compartments
plays a critical role in specifying a signaling outcome
[22, 23]. Consequently, the regulation of receptor deliv-
ery to subsequent endocytic compartments is under
tight spatial and temporal control. Our findings that the
endocytic maturation of the EGFR is intercepted by
hSpry2 indicate that the antagonistic effects of hSpry2
may be exerted through perturbations in the localization
of EGFR signaling. As a consequence of the induced
defect in the exit of activated EGFR from the early endo-
some, hSpry2 expression prevents the accumulation of
active ERK in late endosomes. The significance of signal
propagation through the late endosomes is supported
by the recent finding that the localization of the MP-1/
MAPK scaffold to late endosomes via p14 is required
for full EGF-induced ERK activation and underscores
the significance of signal propagation through the late
endosomes [20].
In biochemical studies, Spry has been shown to po-
tentiate EGFR-induced ERK activation [24, 25]. A priori,
these observations are not consistent with the geneti-
cally ascribed function of Spry as a negative regulator
of EGFR signaling. Our findings provide a possible reso-
lution for this apparent discrepancy by demonstrating
that the localization of EGF-induced ERK activation
rather than the absolute level of activation is the critical
signaling event targeted by hSpry2. In addition to EGFR,
Spry has been shown to antagonize signaling down-
stream of several other RTKs [1]. Because different sig-
naling systems may depend on endosomes to varying
degrees, it remains to be clarified to what extent pertur-
bations in receptor trafficking constitute a more general
mechanism by which Spry exerts its effect on RTK
signaling.
Supplemental Data
Supplemental Data include five figures and Experimental Proce-
dures and are available online at http://www.current-biology.com/
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